SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Transkaryotic(tktx)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: trevor john wilkinson who started this subject12/28/2000 8:49:58 AM
From: Souze   of 122
 
From today's wsj online:

"Genzyme General's share price fell after the company said the Food and Drug Administration wants more information about an unapproved therapy for a rare genetic disease.

The FDA request appears to delay its approval of Genzyme General's enzyme-replacement therapy to treat Fabry disease, a debilitating disorder that afflicts an estimated 2,000 to 4,000 people world-wide.

The stakes are high. Genzyme General, a division of Genzyme Corp., is in a tight race with another Cambridge biotech company, Transkaryotic Therapiest Inc., which is seeking FDA approval for a similar therapy.

Before Genzyme's announcement, analysts expected the Genzyme therapy, Fabrazyme, would be available sometime in the first quarter. Analysts said the FDA action could push that date back six months."
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News